MALT1 inhibition suppresses antigen-specific T cell responses

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Regulatory T-cells (Tregs) play a crucial role in immune suppression within the tumor microenvironment.
• MALT1 (Mucosa-Associated Lymphoid Tissue 1) is a key signaling molecule in T-cell activation and survival.
• Targeting Tregs is a promising strategy for enhancing anti-tumor immunity.

Purpose of the Study:

• To evaluate a selective small molecule MALT1 inhibitor as an immunotherapy targeting Tregs in solid tumors.
• To assess the in vitro and in vivo efficacy of MALT1 inhibition in preclinical cancer models.

Main Methods:

• In vitro assays using Jurkat cells and peripheral blood mononuclear cell (PBMC)-derived Tregs.
• In vivo studies using the MB49 cancer model and an adoptive T-cell transfer model.
• Assessment of MALT1 substrate cleavage, IL-2 secretion, T-cell proliferation, and anti-tumor effects.

Main Results:

• MALT1 inhibition suppressed HOIL1 cleavage and IL-2 secretion in vitro.
• Selective suppression of Treg proliferation was observed, with no impact on conventional CD4+ T-cells.
• MALT1 inhibition alone or with anti-CTLA4 did not yield significant anti-tumor effects in vivo.
• Reduced Treg frequencies in lymph nodes but not within tumors; decreased antigen-specific CD8+ T-cells.

Conclusions:

• Selective MALT1 inhibition alone is insufficient for effective solid tumor immunotherapy.
• Targeting Tregs specifically is necessary to enhance the immunotherapeutic potential of MALT1 inhibitors.
• Further investigation into optimal dosing schedules and combination therapies is warranted.